Literature DB >> 22459838

Minimum inhibitory concentrations of Staphylococcus aureus recovered from clinical and subclinical cases of bovine mastitis.

L Oliveira1, H Langoni, C Hulland, P L Ruegg.   

Abstract

Antimicrobials are often used for treatment of bovine mastitis and the possibility of selection for resistant bacteria must be considered. The objectives of this study were to determine the minimum inhibitory concentration of Staphylococcus aureus recovered from cases of clinical and subclinical bovine mastitis, and to determine the prevalence of multidrug resistance in this population. Milk samples were collected from cows on commercial dairy herds (n=13), including quarters (n=1,574) of cows with subclinical mastitis cases, and cows experiencing clinical mastitis cases (n=608). Selected Staph. aureus isolates, obtained from clinical (n=58) and subclinical (n=58) mastitis cases, were used to determine minimum inhibitory concentrations of 12 selected antimicrobials. Of Staph. aureus isolates tested, 87 (75%) did not exhibit resistance to any antimicrobial, 28 (24.1%) exhibited resistance to 1 (n=21) or 2 (n=7) classes of antimicrobials, and 1 (0.9%) exhibited multidrug resistance. All Staph. aureus (clinical and subclinical cases) were inhibited by the range of concentrations tested for ceftiofur and oxacillin. Moreover, no isolates obtained from clinical mastitis cases exhibited resistance to cephalothin, penicillin-novobiocin, or sulfadimethoxine. Of isolates, 3 exhibited resistance to enrofloxacin. Of isolates exhibiting resistance to more than 1 antimicrobial, independent of antimicrobial class, the combination of erythromycin and tetracycline, and ampicillin and penicillin accounted for the majority of resistance. Of isolates tested, 19% were resistant to tetracycline and 14% were resistant to penicillin. Survival curves of Staph. aureus relative to minimum inhibitory concentration demonstrated heterogeneity among case types for ceftiofur, cephalothin, and erythromycin. Multidrug resistance was identified in only 1 isolate obtained from a single farm.
Copyright © 2012 American Dairy Science Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22459838     DOI: 10.3168/jds.2011-4938

Source DB:  PubMed          Journal:  J Dairy Sci        ISSN: 0022-0302            Impact factor:   4.034


  5 in total

1.  Minocycline enhances the mesenchymal stromal/stem cell pro-healing phenotype in triple antimicrobial-loaded hydrogels.

Authors:  Alberto Daniel Guerra; Warren E Rose; Peiman Hematti; W John Kao
Journal:  Acta Biomater       Date:  2017-01-07       Impact factor: 8.947

2.  Multiresidue screening of milk withheld for sale at dairy farms in central New York State.

Authors:  R V Pereira; J D Siler; R C Bicalho; L D Warnick
Journal:  J Dairy Sci       Date:  2014-01-17       Impact factor: 4.034

3.  Allantodapsone is a Pan-Inhibitor of Staphylococcus aureus Adhesion to Fibrinogen, Loricrin, and Cytokeratin 10.

Authors:  Filippo Prencipe; Aishah Alsibaee; Zainab Khaddem; Padraig Norton; Aisling M Towell; Afnan F M Ali; Gerard Reid; Orla M Fleury; Timothy J Foster; Joan A Geoghegan; Isabel Rozas; Marian P Brennan
Journal:  Microbiol Spectr       Date:  2022-06-01

4.  Dose Assessment of Cefquinome by Pharmacokinetic/Pharmacodynamic Modeling in Mouse Model of Staphylococcus aureus Mastitis.

Authors:  Yang Yu; Yu-Feng Zhou; Xiao Li; Mei-Ren Chen; Gui-Lin Qiao; Jian Sun; Xiao-Ping Liao; Ya-Hong Liu
Journal:  Front Microbiol       Date:  2016-10-07       Impact factor: 5.640

5.  Milk microbial composition of Brazilian dairy cows entering the dry period and genomic comparison between Staphylococcus aureus strains susceptible to the bacteriophage vB_SauM-UFV_DC4.

Authors:  Vinícius da Silva Duarte; Laura Treu; Cristina Sartori; Roberto Sousa Dias; Isabela da Silva Paes; Marcella Silva Vieira; Gabriele Rocha Santana; Marcos Inácio Marcondes; Alessio Giacomini; Viviana Corich; Stefano Campanaro; Cynthia Canedo da Silva; Sérgio Oliveira de Paula
Journal:  Sci Rep       Date:  2020-03-26       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.